If you have started a GLP-1 medication such as Ozempic, Wegovy, Mounjaro or Zepbound and your hair is coming out in the shower, you are not imagining it. Hair loss is listed on the labels of the weight-loss versions of these drugs. The good news is that in most people it is the temporary kind, and it does not mean you have to stop treatment.
This guide sets out what the trials and the newer real-world studies show, why it happens, how long it lasts and what actually helps.
How Common Is Hair Loss on GLP-1 Drugs?
The clearest numbers come from the prescribing information for the two weight-loss brands, which report hair loss from their placebo-controlled trials. Ozempic contains the same drug as Wegovy (semaglutide), and Mounjaro the same as Zepbound (tirzepatide), at doses used for type 2 diabetes.
| Drug and dose | Hair loss on the drug | On placebo | Women on the drug | Men on the drug |
|---|---|---|---|---|
| Wegovy (semaglutide) 2.4 mg weekly | 3.3% | 1% | 4% | 0.9% |
| Wegovy (semaglutide) 7.2 mg weekly | 5.8% | 1.0% | 8.4% | 0.2% |
| Zepbound (tirzepatide) 5-15 mg weekly | 4-5% | 1% | 7.1% | 0.5% |
Sources: Wegovy prescribing information (June 2026) and Zepbound prescribing information (August 2026), via DailyMed.
Three things stand out:
- It is more common than placebo, but still a minority. Roughly one in 20 to one in 30 people on these drugs reported hair loss in the trials.
- It is overwhelmingly a women's side effect. Across both drugs, women reported hair loss several times more often than men.
- The labels tie it to weight loss. Both say that hair loss "was associated with weight reduction", and the higher Wegovy dose, which produces more weight loss, had a higher rate. In the Zepbound trials, no one on the drug stopped treatment because of it.
A 2026 meta-analysis of seven randomized trials and two other intervention studies, covering more than 4,000 people on GLP-1 drugs, found about three times the risk of hair loss compared with placebo, and an overall rate of 3.9% PMID: 42155605.
Is It the Drug or the Weight Loss?
Mostly the weight loss, as far as current evidence goes, though a small direct effect has not been ruled out.
The case for weight loss. Rapid weight loss is a classic trigger for telogen effluvium, whatever causes it. After weight-loss surgery, which takes weight off faster than any drug, a meta-analysis of 18 studies found that 57% of patients reported hair loss, more often younger women and those with low zinc, folate or ferritin PMID: 33675022. The drug labels point the same way, and the dose pattern fits.
The case for something more. A 2026 study in the BMJ compared more than 12,000 adults with type 2 diabetes starting a GLP-1 drug against similar patients starting two other diabetes drugs that cause less weight loss (SGLT-2 and DPP-4 inhibitors). GLP-1 users had a 37% and 68% higher risk of a hair-loss diagnosis, respectively. The link was specific to non-scarring hair loss, weakened after the authors' calibration checks, and the absolute risk was low PMID: 42486607. Studies like this can show an association but cannot fully separate the drug from the weight loss it causes.
For practical purposes, the answer is the same either way: the shedding is usually temporary, and the steps that help are the same.
Why It Happens: Telogen Effluvium
Each hair follicle cycles between a long growing phase and a short resting phase. A shock to the body, such as rapid weight loss, a sharp drop in calories or protein, illness or surgery, can push a large share of follicles into the resting phase at once. Those hairs don't fall immediately. They are shed together about two to three months later, which is why GLP-1 hair loss typically shows up two to four months after starting treatment or increasing the dose, often when the weight loss is fastest.
This is called telogen effluvium PMID: 31686886. It causes diffuse thinning all over the scalp, not bald patches, and it is self-limiting: once the trigger settles, shedding usually stops within three to six months and the hair grows back over the following six to twelve. Our telogen effluvium guide covers it in more detail.
What else can contribute on a GLP-1:
- Eating too little protein and too few nutrients. Appetite suppression is the point of these drugs, but it makes it easy to undereat protein and miss iron, zinc and other nutrients. A 2025 joint advisory from four US obesity and nutrition societies lists nutrient deficiencies and muscle loss among the main challenges of GLP-1 treatment and recommends nutrition support alongside it PMID: 40450457.
- Underlying pattern hair loss. If you already carry the genes for male or female pattern hair loss, a shed can make it visible sooner. See female pattern hair loss.
What Actually Helps
1. Don't stop the medication on your own. The shed is usually temporary, and stopping a GLP-1 typically means regaining weight. Talk to your prescriber first.
2. Eat enough protein and real food. Hair is low-priority tissue, and the body cuts it off first when supplies are short. Build meals around protein, even when your appetite is small, and ask your prescriber or a dietitian for a protein target that fits your weight and kidney health.
3. Get blood tests before buying supplements. Low ferritin (iron stores), thyroid problems, low vitamin D and low zinc all cause or worsen shedding, and all are easy to miss without a test. Correcting a real deficiency helps; adding vitamins you are not short of does not. Our hair loss blood tests guide explains which markers matter.
Before you treat, test
Not sure what's driving your hair loss?
Rapid weight loss on a GLP-1 can drain iron stores and expose thyroid or vitamin D problems that cause shedding of their own. A blood panel tells you whether something other than the weight loss is driving your hair loss, before you spend months on supplements.
4. Talk to your prescriber about the pace. Larger, faster weight loss is linked to more shedding. If your hair loss started after a dose increase, a slower step-up may be an option. That is a medical decision to make with your prescriber, not a reason to change doses yourself.
5. Be patient, and be gentle with your hair. Avoid tight hairstyles, harsh treatments and heat while it recovers. New growth shows up as short, fine hairs along the parting and hairline, usually a few months after the shedding slows.
6. Consider minoxidil if thinning persists. Telogen effluvium usually recovers on its own. But if your hair has not recovered after six months, or the thinning has a pattern (a widening part, a thinning crown, a receding hairline), it may be pattern hair loss that the shed unmasked. Minoxidil is the first-line treatment for that in women and men, and a dermatologist can confirm the diagnosis.
Skip the biotin megadoses. Biotin only helps hair if you are deficient, which is rare, and high doses can distort thyroid and other lab results, which matters when you are trying to find the cause. See biotin for hair loss.
When to See a Doctor
See a doctor or dermatologist if:
- The hair loss is patchy (round bald spots), which suggests alopecia areata or another condition rather than telogen effluvium
- Your scalp is red, scaly, itchy or painful, or the skin looks shiny or scarred
- Shedding continues beyond about six months, or thinning gets worse after your weight has stabilized
- You have other symptoms such as fatigue, feeling cold, or heavy periods, which can point to thyroid problems or iron deficiency
The hormonal and medical causes of hair loss are covered in our guide to hormones and hair loss.
The Bottom Line
Hair loss on Ozempic, Wegovy, Mounjaro or Zepbound is real but usually temporary. It affects a minority of users, mostly women, and is mainly driven by rapid weight loss rather than lasting damage to the follicles. Keep taking your medication unless your prescriber advises otherwise, eat enough protein, check your iron and thyroid, and give it time. If it is patchy, lasts longer than six months or looks like pattern thinning, get it diagnosed, because those are treatable in their own right.
Sources
- Novo Nordisk. Wegovy (semaglutide) prescribing information, section 6.1. Revised June 2026. Via DailyMed, accessed October 23, 2026.
- Eli Lilly. Zepbound (tirzepatide) prescribing information, section 6.1. Revised August 2026. Via DailyMed, accessed October 23, 2026.
- Cheng PL, Chang HC, et al. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2026;237:113333. PMID: 42155605.
- Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. PMID: 42486607.
- Zhang W, Fan M, Wang C, et al. Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis. Obesity Surgery. 2021;31(6):2649-2659. PMID: 33675022.
- Rebora A. Telogen effluvium: a comprehensive review. Clinical, Cosmetic and Investigational Dermatology. 2019;12:583-590. PMID: 31686886.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition. 2025;122(1):344-367. PMID: 40450457.
See also: